OBJECTIVE: To assess CD154 expression in patients with pediatric systemic lupus erythematosus (SLE) and to explore a transcriptional mechanism that may explain dysregulated expression of CD154. METHODS: Cell surface CD154 expression (pre- and postactivation) in peripheral blood CD4 T cells from 29 children with lupus and 29 controls matched for age, sex, and ethnicity was examined by flow cytometry. CD154 expression was correlated with clinical features, laboratory parameters, and treatments received. Increased CD154 expression on CD4 T cells from the SLE patients was correlated with CD154 message and transcription rates by real-time reverse transcription-polymerase chain reaction (RT-PCR) and nuclear run-on assays, respectively. Nuclear factor of activated T cell (NF-AT) transcription activity and mRNA levels in CD4 T cells from SLE patients were explored by reporter gene analysis and real-time RT-PCR, respectively. RESULTS: CD154 surface protein levels were increased 1.44-fold in CD4 T cells from SLE patients as compared with controls in cells evaluated 1 day postactivation ex vivo. This increase correlated clinically with the presence of nephritis and an elevated erythrocyte sedimentation rate. Increased CD154 protein levels also correlated with increased CD154 mRNA levels and with CD154 transcription rates, particularly at later time points following T cell activation. Reporter gene analyses revealed a trend for increased NF-AT, but decreased activator protein 1 and similar NF-kappaB, activity in CD4 T cells from SLE patients as compared with controls. Moreover, NF-AT1 and, in particular, NF-AT2 mRNA levels were notably increased in CD4 T cells from SLE patients as compared with controls. CONCLUSION: Following activation, cell surface CD154 is increased on CD4 T cells from pediatric lupus patients as compared with controls, and this increase correlates with the presence of nephritis, increased CD154 transcription rates, and increased NF-AT activity. These results suggest that NF-AT/calcineurin inhibitors, such as tacrolimus and cyclosporine, may be beneficial in the treatment of lupus nephritis.
OBJECTIVE: To assess CD154 expression in patients with pediatric systemic lupus erythematosus (SLE) and to explore a transcriptional mechanism that may explain dysregulated expression of CD154. METHODS: Cell surface CD154 expression (pre- and postactivation) in peripheral blood CD4 T cells from 29 children with lupus and 29 controls matched for age, sex, and ethnicity was examined by flow cytometry. CD154 expression was correlated with clinical features, laboratory parameters, and treatments received. Increased CD154 expression on CD4 T cells from the SLEpatients was correlated with CD154 message and transcription rates by real-time reverse transcription-polymerase chain reaction (RT-PCR) and nuclear run-on assays, respectively. Nuclear factor of activated T cell (NF-AT) transcription activity and mRNA levels in CD4 T cells from SLEpatients were explored by reporter gene analysis and real-time RT-PCR, respectively. RESULTS:CD154 surface protein levels were increased 1.44-fold in CD4 T cells from SLEpatients as compared with controls in cells evaluated 1 day postactivation ex vivo. This increase correlated clinically with the presence of nephritis and an elevated erythrocyte sedimentation rate. Increased CD154 protein levels also correlated with increased CD154 mRNA levels and with CD154 transcription rates, particularly at later time points following T cell activation. Reporter gene analyses revealed a trend for increased NF-AT, but decreased activator protein 1 and similar NF-kappaB, activity in CD4 T cells from SLEpatients as compared with controls. Moreover, NF-AT1 and, in particular, NF-AT2 mRNA levels were notably increased in CD4 T cells from SLEpatients as compared with controls. CONCLUSION: Following activation, cell surface CD154 is increased on CD4 T cells from pediatric lupuspatients as compared with controls, and this increase correlates with the presence of nephritis, increased CD154 transcription rates, and increased NF-AT activity. These results suggest that NF-AT/calcineurin inhibitors, such as tacrolimus and cyclosporine, may be beneficial in the treatment of lupus nephritis.
Authors: Michael H A Roehrl; Sunghyun Kang; José Aramburu; Gerhard Wagner; Anjana Rao; Patrick G Hogan Journal: Proc Natl Acad Sci U S A Date: 2004-05-06 Impact factor: 11.205
Authors: Troy R Torgerson; Anna Genin; Chunxia Chen; Mingce Zhang; Bin Zhou; Stephanie Añover-Sombke; M Barton Frank; Igor Dozmorov; Elizabeth Ocheltree; Petri Kulmala; Michael Centola; Hans D Ochs; Andrew D Wells; Randy Q Cron Journal: J Immunol Date: 2009-06-29 Impact factor: 5.422
Authors: Vasileios C Kyttaris; Yuang-Taung Juang; Klaus Tenbrock; Arthur Weinstein; George C Tsokos Journal: J Immunol Date: 2004-09-01 Impact factor: 5.422
Authors: Amrie C Grammer; Rebecca Slota; Randy Fischer; Hanan Gur; Hermann Girschick; Cheryl Yarboro; Gabor G Illei; Peter E Lipsky Journal: J Clin Invest Date: 2003-11 Impact factor: 14.808
Authors: Ameet A Chimote; Peter Hajdu; Leah C Kottyan; John B Harley; Yeoheung Yun; Laura Conforti Journal: J Autoimmun Date: 2016-03-16 Impact factor: 7.094
Authors: Samir V Parikh; Ana Malvar; Huijuan Song; Valeria Alberton; Bruno Lococo; Jay Vance; Jianying Zhang; Lianbo Yu; Brad H Rovin Journal: Lupus Sci Med Date: 2015-11-18
Authors: Hani Alrefai; Khalid Muhammad; Ronald Rudolf; Duong Anh Thuy Pham; Stefan Klein-Hessling; Amiya K Patra; Andris Avots; Valesca Bukur; Ugur Sahin; Stefan Tenzer; Matthias Goebeler; Andreas Kerstan; Edgar Serfling Journal: Nat Commun Date: 2016-05-25 Impact factor: 14.919
Authors: Sheng Yan; Lok Yan Yim; Rachel Chun Yee Tam; Albert Chan; Liwei Lu; Chak Sing Lau; Vera Sau-Fong Chan Journal: Int J Mol Sci Date: 2016-08-06 Impact factor: 5.923